Skip to content
Screener

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.3×-0.2×
Pfizer logo
PfizerPFE
1.8×+0.2×
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
5.7×+0.9×
Nuvation Bio logo
Nuvation BioNUVB
7.8×+5.9×
Immunome logo
ImmunomeIMNM
4.6×+1.7×
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
+0.5×

Other financials

Income statement

See full
Operating income-$6.3M-12.4%
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$617.42M+296%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Calculated from Nuvectis Pharma, Inc.’s reported figures.

Based on the most recent quarter.

The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026. Open the filing →

Filed
May 5, 2026, 9:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-055318

FAQ

What is Nuvectis Pharma, Inc.'s price / book?
Nuvectis Pharma, Inc. (NVCT) reported price / book of 14.4× in Q1 2026.
How has Nuvectis Pharma, Inc.'s price / book changed year-over-year?
Nuvectis Pharma, Inc.'s price / book increased by 32.0% year-over-year, from 10.9× to 14.4×.
What is the long-term trend for Nuvectis Pharma, Inc.'s price / book?
Over 3 years (2022 to 2025), Nuvectis Pharma, Inc.'s price / book has grown at a 10.8% compound annual growth rate (CAGR), from 7.7× to 10.5×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Nuvectis Pharma, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude